Dechra Pharmaceuticals Crescita futura

Future criteri di controllo 4/6

Dechra Pharmaceuticals prevede che gli utili e i ricavi cresceranno rispettivamente di 62.5% e 7.9% all'anno. Si prevede che l'EPS crescerà di 89.8% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 19.8% in 3 anni.

Informazioni chiave

62.5%

Tasso di crescita degli utili

89.8%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	19.8%
Tasso di crescita dei ricavi	7.9%
Rendimento futuro del capitale proprio	19.8%
Copertura analitica	Low
Ultimo aggiornamento	03 Jan 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289

Sep 08

Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Aug 18

Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?

Aug 02

These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well

Jun 10

Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)

May 08

Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?

Apr 22

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12

Feb 23

Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 29

Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?

Jan 11

Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly

Dec 04

It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package

Oct 15

Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's

Sep 25

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29

Sep 11

With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting

Sep 08

Is Dechra Pharmaceuticals PLC (LON:DPH) Worth UK£43.4 Based On Its Intrinsic Value?

Jun 17

Is Dechra Pharmaceuticals PLC (LON:DPH) A Smart Choice For Dividend Investors?

Apr 09

Dechra Pharmaceuticals (LON:DPH) Has A Pretty Healthy Balance Sheet

Mar 05

Are Dechra Pharmaceuticals' (LON:DPH) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 17

Dechra Pharmaceuticals PLC (LON:DPH) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Feb 02

Previsioni di crescita degli utili e dei ricavi

LSE:DPH - Stime future degli analisti e dati finanziari passati (GBP Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2026	954	187	N/A	N/A	1
6/30/2025	904	123	160	182	5
6/30/2024	837	102	142	163	2
6/30/2023	762	-28	33	64	N/A
3/31/2023	744	6	39	75	N/A
12/31/2022	727	40	45	86	N/A
9/30/2022	704	49	45	105	N/A
6/30/2022	682	58	45	123	N/A
3/31/2022	661	66	48	121	N/A
12/31/2021	641	73	51	119	N/A
9/30/2021	624	64	3	104	N/A
6/30/2021	608	56	-45	89	N/A
3/31/2021	587	50	-45	102	N/A
12/31/2020	566	44	-44	114	N/A
9/30/2020	541	39	7	110	N/A
6/30/2020	515	34	57	106	N/A
3/31/2020	507	31	57	91	N/A
12/31/2019	499	29	57	76	N/A
9/30/2019	490	30	58	79	N/A
6/30/2019	482	31	59	82	N/A
3/31/2019	463	28	61	82	N/A
12/31/2018	444	25	62	81	N/A
9/30/2018	426	30	57	73	N/A
6/30/2018	407	36	51	64	N/A
3/31/2018	394	40	57	69	N/A
12/31/2017	381	43	63	75	N/A
9/30/2017	370	35	65	76	N/A
6/30/2017	359	26	67	77	N/A
3/31/2017	334	19	N/A	69	N/A
12/31/2016	309	11	N/A	62	N/A
9/30/2016	278	12	N/A	53	N/A
6/30/2016	248	13	N/A	44	N/A
3/31/2016	230	17	N/A	43	N/A
12/31/2015	213	20	N/A	42	N/A
9/30/2015	208	20	N/A	42	N/A
6/30/2015	203	19	N/A	41	N/A
3/31/2015	201	21	N/A	41	N/A
12/31/2014	199	22	N/A	42	N/A
9/30/2014	196	21	N/A	27	N/A
6/30/2014	194	19	N/A	11	N/A
12/31/2013	193	14	N/A	25	N/A
9/30/2013	191	13	N/A	31	N/A
6/30/2013	189	11	N/A	37	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che DPH diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 1.5% ).

Guadagni vs Mercato: Si prevede che DPH diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede DPH diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di DPH ( 7.9% all'anno) crescerà più rapidamente del mercato UK ( 3.5% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di DPH ( 7.9% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di DPH sarà basso tra 3 anni ( 19.8 %).

Dechra Pharmaceuticals Crescita futura

Future criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 10%

Consensus EPS estimates increase by 17%

Consensus EPS estimates increase to UK£0.52

Price target increased to UK£44.46

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Dechra Pharmaceuticals (LON:DPH) Takes On Some Risk With Its Use Of Debt

A Look At The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Consensus EPS estimates fall by 10%

We Think Dechra Pharmaceuticals (LON:DPH) Is Taking Some Risk With Its Debt

Dechra Pharmaceuticals' (LON:DPH) Dividend Will Be Increased To £0.125

Upcoming dividend of UK£0.13 per share at 1.6% yield

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To £0.3289

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Dechra Pharmaceuticals (LON:DPH) Is Paying Out A Larger Dividend Than Last Year

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289

Full year 2022 earnings: EPS misses analyst expectations

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 21% undervalued after recent price drop

These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well

Dechra Pharmaceuticals PLC Announces Executive Changes

Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Less than half of directors are independent

Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?

Non-Executive Chairman recently bought UK£99k worth of stock

Consensus EPS estimates increase by 17%

Upcoming dividend of UK£0.12 per share

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12

First half 2022 earnings: EPS misses analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package

CFO & Executive Director exercised options and sold UK£102k worth of stock

Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's

CEO, MD & Executive Director exercised options and sold UK£841k worth of stock

Board Member recently sold UK£875k worth of stock

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29

With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Consensus EPS estimates increase to UK£0.52

Price target increased to UK£44.46

Is Dechra Pharmaceuticals PLC (LON:DPH) Worth UK£43.4 Based On Its Intrinsic Value?

Board Member recently sold UK£963k worth of stock

Is Dechra Pharmaceuticals PLC (LON:DPH) A Smart Choice For Dividend Investors?